‘Temperature Abuse’ Led Drug Recalls To New Heights In FY 2022, US FDA Finds
Executive Summary
Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.